Brief: Cassava Sciences Q3 Basic EPS USD -0.61

Filana Therapeutics

07/11/2023 14:01

Nov 07 (Reuters) - Cassava Sciences Q3 operating income USD -27.879 million.
* Q3 net income USD -25.651 million
* Q3 operating expenses USD 27.879 million